Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable...

Full description

Bibliographic Details
Main Authors: Mariarosaria Saponaro, Luigi Annunziata, Antonella Turla, Ilaria Viganò, Michele De Laurentiis, Mario Giuliano, Lucia Del Mastro, Filippo Montemurro, Fabio Puglisi, Carmine De Angelis, Giuseppe Buono, Francesco Schettini, Grazia Arpino
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:International Journal of Molecular Sciences
Subjects:
late recurrence
hormone receptor-positive breast cancer
extended endocrine therapy
clinical score
genomic assays
Online Access:https://www.mdpi.com/1422-0067/23/21/13604

Internet

https://www.mdpi.com/1422-0067/23/21/13604

Similar Items